Dr. Jingrong Li is the Chief Technology Officer of GenFleet and responsible for refining the CMC aspects of the company's pipeline to advance drug development, optimize cost and ensure consistent quality. Bringing in over two decades of experiences in the pharmaceutical industry, Dr. Li was involved in numerous programs of approved drugs and diagnostics. His expertise ranges from process development, quality control validation, scale-up manufacturing to other core technologies related with the upstream & downstream sectors of the industry and led various teams to develop preclinical and clinical batches of different monoclonal antibodies, therapeutic vaccines and recombinant protein products.
He received his doctorate degree in China Pharmaceutical University and completed post-doctoral training at Mount Sinai Medical Center in New York. Dr. Li was a professor at China Pharmaceutical University and the distinguished expert of National Medical Products Administration Institute of Executive Development. Prior to entering GenFleet, Dr. Li was the Chief Technology Officer of CStone Pharmaceuticals and the manager principal scientist of Roche Molecular Systems; besides, he also worked in Simcere and BSK Bio.
